Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.

IF 0.9 Q4 HEMATOLOGY

Journal of Clinical and Experimental Hematopathology Pub Date : 2023-01-01 DOI:10.3960/jslrt.23043

Yasunobu Sekiguchi, Hiroki Tsutsumi, Ayumi Gomyo, Masahisa Kudo, Yoshie Iizaki, Nobuo Maseki, Machiko Kawamura, Kazuhiko Kobayashi, Yu Nishimura, Hiroaki Kanda, Hideaki Nitta, Masaaki Noguchi, Hirofumi Kobayashi

引用次数: 0

查看原文本刊更多论文

将 R-mini-CHP 联合 polatuzumab vedotin（pola-R-mini-CHP）作为弥漫大 B 细胞淋巴瘤≥80 岁病例的主要治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical and Experimental Hematopathology HEMATOLOGY-

CiteScore

2.00

自引率

6.70%

发文量

审稿时长

11 weeks